Tivic Health Systems (NASDAQ:TIVC – Get Free Report) will likely be releasing its Q4 2025 resultson Wednesday, April 1st. Analysts expect Tivic Health Systems to post earnings of ($408.00) per share and revenue of $0.46 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:30 PM ET.
Tivic Health Systems Stock Performance
TIVC stock opened at $0.93 on Friday. The business’s 50-day moving average is $0.96 and its two-hundred day moving average is $1.81. Tivic Health Systems has a fifty-two week low of $0.72 and a fifty-two week high of $13.23. The company has a market cap of $1.65 million, a price-to-earnings ratio of -0.14 and a beta of 2.01.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tivic Health Systems in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Tivic Health Systems has an average rating of “Sell”.
About Tivic Health Systems
Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.
The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.
See Also
Receive News & Ratings for Tivic Health Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tivic Health Systems and related companies with MarketBeat.com's FREE daily email newsletter.
